1Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation [ J]. Nature ,2008,454(7203 ) :436 - 444.
2Jemal A, Siegel R, Ward E, et al. Cancer statistics [ J ]. CA Cancer J Clin, 2008,58 ( 2 ) : 71 - 96.
3Sueblinvong T, Carney ME. Current understanding of risk factors for ovarian cancer [ J]. Curr Treat Options Oneol, 2009,10(1-2) :67 - 81.
4Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women [ J]. Gynecol Oncol,2002,87 ( 1 ) :52 - 56.
5Medeiros F, Muto MG,Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome [J]. Am J Surg Pathol, 2006,30 (2) : 230 - 236.
6Sogaard M, Kjaer SK, Gayther S. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention [ J]. Acta Obstet Gynecol Scand, 2006, 85 ( 1 ) :93 - 105.
7Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers [ J]. Gynecol Oncol,2006, 100(1) :58 -64.
8Carcangiu ML, Peissel B, Pasini B, et al. Incidental carcinomas in prophylactic specimens in BIICA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions, report of 6 cases and review of the literature [J]. Am J Surg Pathol,2006,30 (10) : 1222 - 1230.
9Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube [ J]. J Pathol,2007,211 ( 1 ) :26 - 35.
10Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship [ J ]. Am J Surg Pathol, 2007,31 (2) :161 - 169.
2Malpica A, Deavers M T, Lu K, et al. Grading ovarian serouscarcinoma using a two-tier system[ J]. Am J Surg Pathol,2004,28(4) :496 -504.
3Malpica A, Deavers M T, Tomos C, et al. Interobserver and in-traobserver variability of a two-tier system for grading ovarian se-rous carcinoma[ J]. Am J Surg Pathol,2007,31 (8) :1168 -74.
4Seidman J D, Horkayne-Szakaly I,Cosin J A, et al. Testing oftwo binary grading systems for FIGO stage M serous carcinoma ofthe ovary and peritoneum[ J]. Gynecol Oncol, 2006,103(2) :703-8.
5Vang R, Shih Ie M, Kurman R J. Ovarian low-grade and high-grade serous carcinoma : pathogenesis, clinicopathologic and mo-lecular biologic features,and diagnostic problems [ J]. Adv AnatPathol, 2009,16(5):267 -82.
6Ayhan A, kurman R J, Yemelyanova A, et al. Defining the cutpoint between low-grade and high-grade ovarian serous carcino-mas; a clinicopathologic and molecular genetic analysis[ J]. Am JSurg Pathol,2009,33(8); 1220 - 4.
7Przybycin C G, Kurman R J, Ronnett B M, ei al. Are all pelvic(non uterine) serous carcinomas of tubal origin [ J]? Am J SurgPathol, 2010,34(10):1407-16.
8Dubeau L. The cell of origin of ovarian epithelial tumors[ J]. Lan-cet Oncol, 2008,9(12) ;1191 -7.
9Kurman R J, Shih Ie M. Pathogenesis of ovarian cancer: lessonsfrom morphology and molecular biology and their clinical implica-tions[J]. Int J Gynecol Pathol, 2008,27(2) :151 -60.
10Mavaddat N,Barrowdale D,Andrulis I L,ei al. Pathology ofbreast and ovarian cancers among BHCA1 and BRCA2 mutationcarriers : results from the consortium of investigators of modifiers ofBRCA1/2 ( CIMBA) [ J ]. Cancer Epidemiol Biomarkers Prev,2012,21(l):134 -47.
